A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma^*

References

• WHO. Glaucoma is the second leading cause of blindness globally. http://www.who.int/bulletin/volumes/82/11/feature1104/en/print.html. 2004. Ref Type: Internet Communication1. WHO. Glaucoma is the second leading cause of blindness globally. http://www.who.int/bulletin/volumes/82/11/feature1104/en/print.html. 2004. Ref Type: Internet Communication
   Google Scholar
• Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma 2007;16:406–182. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma 2007;16:406–18
   PubMed Web of Science ®Google Scholar
• Tuck MW, Crick RP. The projected increase in glaucoma due to an ageing population. Ophthalmic Physiol Opt 2003;23:175–93. Tuck MW, Crick RP. The projected increase in glaucoma due to an ageing population. Ophthalmic Physiol Opt 2003;23:175–9
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499–5044. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499–504
   PubMed Web of Science ®Google Scholar
• Leske MC, Connell AM, Schachat AP, et al. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821–95. Leske MC, Connell AM, Schachat AP, et al. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821–9
   PubMed Web of Science ®Google Scholar
• Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension. http://www rcophth ac uk/about/publications/20046. Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension. http://www rcophth ac uk/about/publications/2004
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17:1–127. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17:1–12
   PubMedGoogle Scholar
• Carpineto P, Ciancaglini M, Zuppardi E, et al. The role of the uveoscleral outflow in the management of pigmentary glaucoma: a 24-month study comparing latanoprost with timolol. Acta Ophthalmol Scand 2000;( Suppl 232):548. Carpineto P, Ciancaglini M, Zuppardi E, et al. The role of the uveoscleral outflow in the management of pigmentary glaucoma: a 24-month study comparing latanoprost with timolol. Acta Ophthalmol Scand 2000;(Suppl 232):54
   Google Scholar
• Polo V, Larrosa JM, Gomez ML, et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001;79:6–99. Polo V, Larrosa JM, Gomez ML, et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001;79:6–9
   PubMedGoogle Scholar
• Ritch R. The International Collaborative Exfoliation Syndrome (XFS) Treatment Study (ICEST): study design, methods, and baseline data of enrolled patients. (2004). IOVS. 2004. Ref Type: Abstract10. Ritch R. The International Collaborative Exfoliation Syndrome (XFS) Treatment Study (ICEST): study design, methods, and baseline data of enrolled patients. (2004). IOVS. 2004. Ref Type: Abstract
   Google Scholar
• Tomita G, Araie M, Kitazawa Y, et al. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye 2004;18:984–911. Tomita G, Araie M, Kitazawa Y, et al. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye 2004;18:984–9
   PubMed Web of Science ®Google Scholar
• Ang A, Reddy MA, Shepstone L, et al. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 2004;88:630–412. Ang A, Reddy MA, Shepstone L, et al. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 2004;88:630–4
   PubMed Web of Science ®Google Scholar
• Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710–313. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710–3
   PubMed Web of Science ®Google Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension [The Latanoprost Study Group]. Ophthalmology 1996;103:126–3714. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension [The Latanoprost Study Group]. Ophthalmology 1996;103:126–37
   PubMed Web of Science ®Google Scholar
• Akarsu C, Bilgili YK, Taner P, et al. Short-term effect of latanoprost on ocular circulation in ocular hypertension. Clin Experiment Ophthalmol 2004;32:373–715. Akarsu C, Bilgili YK, Taner P, et al. Short-term effect of latanoprost on ocular circulation in ocular hypertension. Clin Experiment Ophthalmol 2004;32:373–7
   PubMed Web of Science ®Google Scholar
• Erkin EF, Tarhan S, Kayikcioglu OR, et al. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 2004;14:211–916. Erkin EF, Tarhan S, Kayikcioglu OR, et al. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 2004;14:211–9
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550–517. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550–5
   PubMed Web of Science ®Google Scholar
• Kitnarong N, Zhao Y, Netland PA, et al. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther 2004;21:203–1318. Kitnarong N, Zhao Y, Netland PA, et al. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther 2004;21:203–13
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566–7319. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566–73
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453–720. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453–7
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601–821. Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601–8
   PubMed Web of Science ®Google Scholar
• Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 2008;92:7–1222. Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 2008;92:7–12
   PubMed Web of Science ®Google Scholar
• Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005;21:1875–8323. Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005;21:1875–83
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003;25:1172–8524. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003;25:1172–85
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137 Suppl 1:S3–S1225. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137 Suppl 1:S3–S12
   PubMed Web of Science ®Google Scholar